h1

% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@PHDTHESIS{Syben:1023672,
      author       = {Syben, Annabell},
      othercontributors = {Rolke, Roman and Mücke, Martin},
      title        = {{N}ervencheck zur {F}rühdiagnostik einer
                      {C}hemotherapie-induzierten {N}europathie ({N}-{CHECK})},
      school       = {Rheinisch-Westfälische Technische Hochschule Aachen},
      type         = {Dissertation},
      address      = {Aachen},
      publisher    = {RWTH Aachen University},
      reportid     = {RWTH-2025-10656},
      pages        = {1 Online-Ressource : Illustrationen},
      year         = {2025},
      note         = {Veröffentlicht auf dem Publikationsserver der RWTH Aachen
                      University 2026; Dissertation, Rheinisch-Westfälische
                      Technische Hochschule Aachen, 2025},
      abstract     = {Chemotherapy-induced neuropathy (CIPN) is a common side
                      effect of platinum based cytostatic therapies. It
                      encompasses a spectrum of symptoms ranging from hypaesthesia
                      with impaired gait, stance and fine motor skills to painful
                      dysaesthesia and allodynia and significantly impairs the
                      quality of life of those affected. In around a third of
                      patients, CIPN develops into a chronic condition. To date,
                      there are neither proven effective preventive strategies nor
                      a standardised procedure for diagnosis and treatment. In our
                      pilot study " Nerve check for early diagnosis of a
                      chemotherapy-induced neuropathy (N-CHECK)”, CIPN was
                      investigated as a common adverse effect of platinum
                      derivatives in patients with solid tumours using
                      quantitative sensory testing (QST) according to the
                      standardised examination protocol of the German Research
                      Network on Neuropathic Pain (DFNS). The QST examines thermal
                      and mechanical perception and pain thresholds to record the
                      subjectively experienced pain phenotype. In N-CHECK it was
                      used before and six to ten weeks after the start of the
                      potentially CIPN-inducing therapy and the data collected was
                      compared in a pre-post analysis. In addition, the Eastern
                      Cooperative Oncology Group Performance Status (ECOG PS), the
                      German short form of the Patient Health Questionnaire
                      (PHQ-D) for screening anxiety and depression, and the
                      Functional Assessment for Cancer Therapy - General (FACT-G)
                      for assessing cancer-specific health-related quality of life
                      were used as criteria for the toxicity of the platinum
                      derivatives. To shed light on the current state of research
                      regarding CIPN, a systematic literature review was
                      completed. Overall, the patients showed significant new heat
                      hypoalgesia after the start of chemotherapy as a sign of
                      damage to small nerve fibres. In addition, there was a
                      reduction in physical functioning and a significantly higher
                      level of suffering from the side effects of the therapy.
                      There were indications of a deterioration in the quality of
                      life and impairment of the mental health of individuals. The
                      systematic literature review emphasised the need for further
                      research to be able to help CIPN patients at an early stage.
                      This pilot study provided a basis for the early diagnosis of
                      chemotherapy-induced neuropathy. Further research is needed
                      to validate the results so that the diagnosis of CIPN can be
                      improved and patients can be treated earlier and in a more
                      targeted manner.},
      cin          = {534500-2 ; 934810},
      ddc          = {610},
      cid          = {$I:(DE-82)534500-2_20140620$},
      typ          = {PUB:(DE-HGF)11},
      doi          = {10.18154/RWTH-2025-10656},
      url          = {https://publications.rwth-aachen.de/record/1023672},
}